{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:23:37Z","timestamp":1791941017531,"version":"4.3.4"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec id=\"ab-zsc250003-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Immunocompromised individuals are a large and growing population who are at increased risk for infectious diseases. There has and continues to be a lack of focus on clinical trials to establish the safety and efficacy of therapies for infectious diseases in immunocompromised patients. The establishment of a US-based clinical trial network to improve the study and subsequent implementation of therapies and strategies to treat and prevent infections in immunocompromised individuals would address this gap in research infrastructure and jumpstart public and private investment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zsc250003-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>A national interdisciplinary meeting was convened on September 10, 2024, in Bethesda, Maryland, to discuss the outsized impact of infectious diseases in immunocompromised individuals and to identify the primary gaps and opportunities for clinical trials in this population. Approaches to achieve this goal include obtaining dedicated funding and support through public-private partnerships to establish alignment and feasibility for high-priority areas of research. This article outlines the relevance of this work; ongoing efforts to collaborate with the National Institutes of Health, US Congress, industry, and philanthropy to obtain funding for mutually beneficial outcomes; the network structure; and perspectives from clinicians, regulatory agencies, the pharmaceutical industry, and patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-zsc250003-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>There is a dearth of evidence to support the use of many therapies for infectious diseases in immunocompromised individuals, which has substantial impact at the individual and societal level. A multipronged approach to improve integration of, and funding for, rigorous research in this population into the core priorities of the public and private sectors could address important public health gaps by developing evidence-based guidance to protect a vulnerable community.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.28383","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:30:33Z","timestamp":1755876633000},"page":"e2528383","source":"Crossref","is-referenced-by-count":12,"title":["A Network for Advancing Prevention and Treatment of Infections Among Immunocompromised Individuals"],"prefix":"10.1001","volume":"8","author":[{"given":"Joshua A.","family":"Hill","sequence":"first","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Pergam","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha B.","family":"Halasa","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepali","family":"Kumar","sequence":"additional","affiliation":[{"name":"University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey R.","family":"Baden","sequence":"additional","affiliation":[{"name":"Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Harvard University, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Boeckh","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"University of Washington School of Medicine, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"7","key":"zsc250003r1","doi-asserted-by":"publisher","first-page":"e1302","DOI":"10.1093\/cid\/ciaa1189","article-title":"Immunosuppressive agents and infectious risk in transplantation: managing the \u201cnet state of immunosuppression\u201d.","volume":"73","author":"Roberts","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"3","key":"zsc250003r2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2024.01.009","article-title":"Disparities in COVID-19 mortality amongst the immunosuppressed: a systematic review and meta-analysis for enhanced disease surveillance.","volume":"88","author":"Leston","year":"2024","journal-title":"J Infect"},{"key":"zsc250003r3","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae435","article-title":"2024 Clinical practice guideline update by the Infectious Diseases Society of America on the management of COVID-19: anti-SARS-CoV-2 neutralizing antibody pemivibart for pre-exposure prophylaxis.","author":"Bhimraj","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"7","key":"zsc250003r4","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/bloodadvances.2020001470","article-title":"Late infectious complications in hematopoietic cell transplantation survivors: a population-based study.","volume":"4","author":"Foord","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"zsc250003r5","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/ajt.14208","article-title":"Infection in organ transplantation.","volume":"17","author":"Fishman","year":"2017","journal-title":"Am J Transplant"},{"issue":"9","key":"zsc250003r6","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13526","article-title":"Herpes simplex virus infections in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Lee","year":"2019","journal-title":"Clin Transplant"},{"issue":"9","key":"zsc250003r7","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13622","article-title":"Varicella zoster virus in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Pergam","year":"2019","journal-title":"Clin Transplant"},{"issue":"9","key":"zsc250003r8","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512","article-title":"Cytomegalovirus in solid organ transplant recipients: guidelines of the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Razonable","year":"2019","journal-title":"Clin Transplant"},{"issue":"9","key":"zsc250003r9","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13511","article-title":"RNA respiratory viral infections in solid organ transplant recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Manuel","year":"2019","journal-title":"Clin Transplant"},{"issue":"5","key":"zsc250003r10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11908-022-00778-1","article-title":"Challenges of antimicrobial resistance and stewardship in solid organ transplant patients.","volume":"24","author":"So","year":"2022","journal-title":"Curr Infect Dis Rep"},{"issue":"2","key":"zsc250003r12","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1016\/j.ajt.2023.02.003","article-title":"OPTN\/SRTR 2021 annual data report: introduction.","volume":"23","author":"Schladt","year":"2023","journal-title":"Am J Transplant"},{"issue":"23","key":"zsc250003r13","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1001\/jama.2016.16477","article-title":"Prevalence of Immunosuppression Among US Adults, 2013.","volume":"316","author":"Harpaz","year":"2016","journal-title":"JAMA"},{"issue":"8","key":"zsc250003r14","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.3201\/eid2608.191493","article-title":"Analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States.","volume":"26","author":"Patel","year":"2020","journal-title":"Emerg Infect Dis"},{"issue":"10","key":"zsc250003r15","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1001\/jama.2023.28019","article-title":"Prevalence of immunosuppression among US adults.","volume":"331","author":"Martinson","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"zsc250003r16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1056\/NEJMsb2104756","article-title":"SARS-CoV-2 variants in patients with immunosuppression.","volume":"385","author":"Corey","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"zsc250003r17","doi-asserted-by":"publisher","DOI":"10.1172\/JCI168603","article-title":"SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern.","volume":"133","author":"Casadevall","year":"2023","journal-title":"J Clin Invest"},{"issue":"3","key":"zsc250003r18","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1473-3099(11)70318-8","article-title":"Antiviral resistance during the 2009 influenza A H1N1 pandemic: public health, laboratory, and clinical perspectives.","volume":"12","author":"Hurt","year":"2012","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"zsc250003r19","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3201\/eid1704.101429","article-title":"H275Y mutant pandemic (H1N1) 2009 virus in immunocompromised patients.","volume":"17","author":"Renaud","year":"2011","journal-title":"Emerg Infect Dis"},{"issue":"4","key":"zsc250003r20","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41579-021-00639-z","article-title":"Infectious disease in an era of global change.","volume":"20","author":"Baker","year":"2022","journal-title":"Nat Rev Microbiol"},{"issue":"10439","key":"zsc250003r21","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(24)00532-4","article-title":"A measles and rubella vaccine microneedle patch in the Gambia: a phase 1\/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.","volume":"403","author":"Adigweme","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"zsc250003r22","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41417-022-00435-8","article-title":"Next generation self-replicating RNA vectors for vaccines and immunotherapies.","volume":"30","author":"Aliahmad","year":"2023","journal-title":"Cancer Gene Ther"},{"issue":"3","key":"zsc250003r23","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1873","article-title":"Improved cancer immunotherapy strategies by nanomedicine.","volume":"15","author":"Guo","year":"2023","journal-title":"Wiley Interdiscip Rev Nanomed Nanobiotechnol"},{"issue":"7929","key":"zsc250003r24","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41586-022-05216-9","article-title":"Long-primed germinal centres with enduring affinity maturation and clonal migration.","volume":"609","author":"Lee","year":"2022","journal-title":"Nature"},{"issue":"5","key":"zsc250003r25","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3390\/v15051199","article-title":"Efficacy of remdesivir and neutralizing monoclonal antibodies in monotherapy or combination therapy in reducing the risk of disease progression in elderly or immunocompromised hosts hospitalized for COVID-19: a single center retrospective study.","volume":"15","author":"Bavaro","year":"2023","journal-title":"Viruses"},{"issue":"4","key":"zsc250003r26","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1097\/QCO.0000000000000846","article-title":"Monoclonal antibodies for prophylaxis and treatment of respiratory viral infections.","volume":"35","author":"Boonyaratanakornkit","year":"2022","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"zsc250003r27","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41467-023-36459-3","article-title":"Cross-protective antibodies against common endemic respiratory viruses.","volume":"14","author":"Cab\u00e1n","year":"2023","journal-title":"Nat Commun"},{"issue":"3","key":"zsc250003r28","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood.2021012249","article-title":"Cellular therapies for the treatment and prevention of SARS-CoV-2 infection.","volume":"140","author":"Conway","year":"2022","journal-title":"Blood"},{"issue":"9","key":"zsc250003r29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/blood.2019000924","article-title":"Virus-specific T-cell therapies for patients with primary immune deficiency.","volume":"135","author":"Keller","year":"2020","journal-title":"Blood"},{"issue":"3","key":"zsc250003r30","doi-asserted-by":"publisher","DOI":"10.1111\/tid.14051","article-title":"Cowpox to COVID: history of vaccination in the immunocompromised host.","volume":"25","author":"Schaenman","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"2","key":"zsc250003r31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/1574884712666170809124728","article-title":"Monoclonal antibodies: a review.","volume":"13","author":"Singh","year":"2018","journal-title":"Curr Clin Pharmacol"},{"issue":"4","key":"zsc250003r32","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/cid\/ciae308","article-title":"How immunocompromised hosts were left behind in the quest to control the COVID-19 pandemic.","volume":"79","author":"Boeckh","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"5","key":"zsc250003r33","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1001\/jama.2024.25395","article-title":"Antibody response to respiratory syncytial virus vaccination in immunocompromised persons.","volume":"333","author":"Karaba","year":"2025","journal-title":"JAMA"},{"issue":"6","key":"zsc250003r34","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1473-3099(24)00796-5","article-title":"Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study.","volume":"25","author":"Bajema","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"zsc250003r35","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.3390\/molecules26041132","article-title":"Advances and perspectives in the management of Varicella zoster virus infections.","volume":"26","author":"Andrei","year":"2021","journal-title":"Molecules"},{"issue":"9","key":"zsc250003r36","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.cmi.2022.05.005","article-title":"Immunocompromised patients have been neglected in COVID-19 trials: a call for action.","volume":"28","author":"Tr\u00f8seid","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"zsc250003r37","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijid.2023.06.021","article-title":"Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations.","volume":"134","author":"Cowan","year":"2023","journal-title":"Int J Infect Dis"},{"issue":"2","key":"zsc250003r38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S1083-8791(00)70070-X","article-title":"Clinical trials of hematopoietic cell transplantations: current needs and future strategies.","volume":"6","author":"O\u2019Reilly","year":"2000","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"zsc250003r39","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1200\/JCO.20.01623","article-title":"Building a fit for purpose clinical trials infrastructure to accelerate the assessment of novel hematopoietic cell transplantation strategies and cellular immunotherapies.","volume":"39","author":"Devine","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"zsc250003r40","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.bbmt.2016.07.003","article-title":"The Blood and Marrow Transplant Clinical Trials Network: an effective infrastructure for addressing important issues in hematopoietic cell transplantation.","volume":"22","author":"Steering Committee Of The Blood And Marrow Transplant Clinical Trials Network","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"zsc250003r41","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4155\/cli.12.8","article-title":"HIV Vaccine Trials Network: activities and achievements of the first decade and beyond.","volume":"2","author":"Kublin","year":"2012","journal-title":"Clin Investig (Lond)"},{"issue":"17","key":"zsc250003r42","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/jama.2024.5570","article-title":"Introducing the JAMA Summit.","volume":"331","author":"Bibbins-Domingo","year":"2024","journal-title":"JAMA"},{"issue":"2","key":"zsc250003r43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1001\/jama.2024.4088","article-title":"The integration of clinical trials with the practice of medicine: repairing a house divided.","volume":"332","author":"Angus","year":"2024","journal-title":"JAMA"},{"issue":"8003","key":"zsc250003r44","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1038\/d41586-024-00753-x","article-title":"How AI is being used to accelerate clinical trials.","volume":"627","author":"Hutson","year":"2024","journal-title":"Nature"},{"issue":"9","key":"zsc250003r45","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae473","article-title":"Defining the landscape of educational experiences in transplant infectious diseases: a national survey of infectious diseases fellows in the United States.","volume":"11","author":"Phadke","year":"2024","journal-title":"Open Forum Infect Dis"},{"issue":"3","key":"zsc250003r46","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1200\/JCO.2015.62.0468","article-title":"Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors.","volume":"34","author":"Yabroff","year":"2016","journal-title":"J Clin Oncol"},{"issue":"5","key":"zsc250003r47","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1200\/JCO.22.00461","article-title":"Financial burden in blood or marrow transplantation survivors during the COVID-19 pandemic: a BMTSS report.","volume":"41","author":"Bhatia","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"zsc250003r49","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cell.2016.06.029","article-title":"Roots, not parachutes: research collaborations combat outbreaks.","volume":"166","author":"Yozwiak","year":"2016","journal-title":"Cell"},{"key":"zsc250003r11","unstructured":"Bolon? YT, Atshan? R, Allbee-Johnson? M, Estrada-Merly? N, Lee? SJ. 2022 US summary slides (PowerPoint). Center for International Blood & Marrow Transplant Research. Accessed July 22, 2025. https:\/\/cibmtr.org\/CIBMTR\/Resources\/Summary-Slides-Reports"},{"key":"zsc250003r48","unstructured":"European Medicines Agency. Clinical evaluation of new vaccines\u2014scientific guideline. January 8, 2023. Accessed July 23, 2025. https:\/\/www.ema.europa.eu\/en\/clinical-evaluation-new-vaccines-scientific-guideline"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837934\/hill_2025_sc_250003_1755198186.67247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:30:34Z","timestamp":1755876634000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837934"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.28383","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]}}}